X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

By Jocelyn Ulrich  |    January 24, 2022
New research published in The Lancet shows for the first time the global impact of antimicrobial resistance (AMR), which poses an increasingly serious threat to human health around the world. The...   Read More

New data show continued decline in death rates for cancer patients related to treatment advances

By Andrew Powaleny  |    January 20, 2022
According to a new report from American Cancer Society (ACS), death rates for cancer patients in the United States continue to decrease. Each year, ACS details a range of incidence, mortality and...   Read More

New Report: Nearly 800 new medicines in development to treat rare diseases

By Andrew Powaleny  |    December 16, 2021
Today, PhRMA released a new report detailing orphan drug development in the U.S. and the potential to meet the significant unmet medical need for patients. Rare diseases and conditions...   Read More

Recap: Our inaugural graduate summit and career expo

By Dr. Steven Thomas  |    December 8, 2021
On October 27 and 28, 2021, PhRMA held our inaugural graduate summit and career expo, Pathways to Success in Biopharma. As part of a joint partnership between PhRMA, CHI, UNCF and the Ernest E....   Read More

New report details the promise of the biopharmaceutical pipeline

By Abigail Lore  |    December 7, 2021
The biopharmaceutical pipeline contains thousands of innovative new treatments that have the potential to address unmet medical needs, save lives and improve patients’ health. A new report by the...   Read More

3 things to know about the importance of post-approval research and development

By Andrew Powaleny  |    December 6, 2021
Despite tremendous progress and knowledge gained from post-approval R&D, some in Congress still fail to recognize innovation doesn’t stop at U.S. Food and Drug Administration (FDA) approval. After...   Read More

World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS

By Andrew Powaleny  |    December 1, 2021
Today, as we mark World AIDS Day and commemorate those who lost their lives to AIDS-related illnesses, we want to recognize the impressive advancements in HIV/AIDS scientific research and drug...   Read More

Guest post: Congress should not put future innovation at risk

By Guest Contributor  |    November 29, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

By Jocelyn Ulrich  |    November 18, 2021
COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract. Over the past 100 years, pandemics have been caused by novel forms of influenza and...   Read More

New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

By Tim McClung  |    November 1, 2021
A new report from NDP Analytics showcases how innovation is the lifeblood of economic growth in the United States and that intellectual property (IP) protections are a crucial driver for high...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates